KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $96.5 million.

  • AbCellera Biologics' Other Non-Current Assets fell 60.46% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 60.46%. This contributed to the annual value of $96.5 million for FY2024, which is 2.43% up from last year.
  • According to the latest figures from FY2024, AbCellera Biologics' Other Non-Current Assets is $96.5 million, which was up 2.43% from $94.2 million recorded in FY2023.
  • Over the past 5 years, AbCellera Biologics' Other Non-Current Assets peaked at $96.5 million during FY2024, and registered a low of $8.4 million during FY2020.
  • In the last 3 years, AbCellera Biologics' Other Non-Current Assets had a median value of $94.2 million in 2023 and averaged $79.0 million.
  • Data for AbCellera Biologics' Other Non-Current Assets shows a peak YoY soared of 265.31% (in 2021) over the last 5 years.
  • AbCellera Biologics' Other Non-Current Assets (Yearly) stood at $8.4 million in 2020, then skyrocketed by 265.31% to $30.6 million in 2021, then soared by 51.20% to $46.3 million in 2022, then surged by 103.41% to $94.2 million in 2023, then rose by 2.43% to $96.5 million in 2024.